Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics

Allergy, Asthma and Immunology Research

Volumn 2, Issue 1, 2010, Pages 48-54

  Park, Jong Sook ^a   Jang, An Soo ^a   Park, Sung Woo ^a   Lee, Young Mok ^a   Uh, Soo Taek ^a   Kim, Yong Hoon ^b   Cha, Ji Yean ^b   Park, Se Min ^b   Park, Choon Sik ^a,b  

^a Soonchunhyang University College of Medicine   (South Korea)

^b Soonchunhyang University   (South Korea)

Author keywords

Aspirin; Asthma; Eosinophils; Leukotriene antagonists

Indexed keywords

ACETYLSALICYLIC ACID; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR AFFECTING AGENT; MONTELUKAST;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PROVOCATION TEST; RECOMMENDED DRUG DOSE; SINUSITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77952788524     PISSN: 20927355     EISSN: 20927363     Source Type: Journal    
DOI: 10.4168/aair.2010.2.1.48     Document Type: Article

References (33)

1. Samter M, Beers RF. Concerning the nature of intolerance to aspirin. J Allergy 1967;40:281-293
2. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Asthma Allergy Clin Immunol 2003;111:913-21;quiz 922. (Pubitemid 36570845)
3. Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L; TENOR Study Group. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005;116:970-975 (Pubitemid 41571774)
4. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin- sensitive rhinosinusitis. N Engl J Med 2002;347:1493-1499 (Pubitemid 35257588)
5. Picado C. Aspirin-intolerant asthma: role of cyclo-oxygenase enzymes. Allergy 2002;S72:58-60. (Pubitemid 34970039)
6. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990;3:588-593
7. Arm JP, O'Hickey SP, Spur BW, Lee TH. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am Rev Respir Dis 1989;140:148-153
8. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206. (Pubitemid 29063217)
9. Leff AR. Regulation of leukotrienes in the management of asthma: biology and clinical therapy. Annu Rev Med 2001;52:1-14.
10. Hui Y, Funk CD. Cysteinyl leukotriene receptors. Biochem Pharmacol 2002;64:1549-1557
11. Nayak A. A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin Pharmacother 2004;5:679-686 (Pubitemid 38344321)
12. Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, Tozzi CA, Polos P. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005;171:315-322 (Pubitemid 40223397)
13. Israel E, Chervinsky PS, Friedman B, van Bavel J, Skalky CS, Ghannam AF, Bird SR, Edelman JM. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002;110:847-854 (Pubitemid 36005870)
14. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, Zeiger RS, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005;115:233-242 (Pubitemid 40215084)
15. Dahlén SE, Malmström K, Nizankowska E, Dahlén B, Kuna P, Kowalski M, Lumry WR, Picado C, Stevenson DD, Bousquet J, Pauwels R, Holgate ST, Shahane A, Zhang J, Reiss TF, Szczeklik A. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9-14.
16. Cristie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991;144:957-958
17. Yoshida S, Sakamoto H, Ishizaki Y, Onuma K, Shoji T, Nakagawa H, Nakabayashi M, Amayasu H. Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma. Clin Exp Allergy 2000;30:64-70.
18. Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 2002;32:1491-1496
19. White A, Ludington E, Mehra P, Stevenson DD, Simon RA. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol 2006;97:688-693
20. Micheletto C, Tognella S, Visconti M, Pomari C, Trevisan F, Dal Negro RW. Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. Allergy 2004;59:289-294
21. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health; 1997. NIH publication no. 97-4051A.
22. Stevenson DD. Aspirin-sensitive Asthma. In: Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ, editors, Asthma. New York: Lippincott-Raven; 1997. p. 2025-2040
23. Cormican LJ, Farooque S, Altmann DR, Lee TH. Improvement in an oral aspirin challenge protocol for the diagnosis of aspirin hypersensitivity. Clin Exp Allergy 2005;35:717-722 (Pubitemid 40961342)
24. Metters KM. Leukotriene receptors. J Lipid Mediat Cell Signal 1995;12:413-427
25. Dahlén B, Nizankowska E, Szczeklik A, Zetterström O, Bochenek G, Kumlin M, Mastalerz L, Pinis G, Swanson LJ, Boodhoo TI, Wright S, Dubé LM, Dahlén SE. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998;157:1187-1194 (Pubitemid 28225187)
26. White AA, Stevenson DD, Simon RA. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005;95:330-335
27. Nasser SM, Pfister R, Christie PE, Sousa AR, Barker J, Schmitz-Schumann M, Lee TH. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996;153:90-96 (Pubitemid 26026832)
28. Park HS, Nahm DH, Park K, Suh KS, Yim HE. Immunohistochemical characterization of cellular infiltrate in nasal polyp from aspirin-sensitive asthmatic patients. Ann Allergy Asthma Immunol 1998; 81:219-224
29. Nasser S, Christie PE, Pfister R, Sousa AR, Walls A, Schmitz-Schumann M, Lee TH. Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects. Thorax 1996;51:64-70. (Pubitemid 26047104)
30. Pods R, Ross D, van Hülst S, Rudack C, Maune S. RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad. Allergy 2003;58:1165-1170 (Pubitemid 37372303)
31. Min JW, Jang AS, Park SM, Lee SH, Lee JH, Park SW, Park CS. Comparison of plasma eotaxin family level in aspirin-induced and aspirin-tolerant asthma patients. Chest 2005;128:3127-3132
32. Fujii M, Tanaka H, Abe S. Interferon-gamma up-regulates expression of cysteinyl leukotriene type 2 receptors on eosinophils in asthmatic patients. Chest 2005;128:3148-3155 (Pubitemid 41698634)
33. Obase Y, Shimoda T, Tomari S, Mitsuta K, Fukushima C, Kawano T, Matsuse H, Kohno S. Effects of pranlukast on aspirin-induced bronchoconstriction: differences in chemical mediators between aspirin-intolerant and tolerant asthmatic patients. Ann Allergy Asthma Immunol 2001;87:74-79 (Pubitemid 32678340)